A new oral medication for people with IPF
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a new oral medication, HSK44459, for people with IPF. It aims to see if the drug is safe and effective compared to a placebo, and might help slow the progression of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 40 years old.
- You have a confirmed diagnosis of IPF (idiopathic pulmonary fibrosis).
- You either haven't taken pirfenidone or nintedanib for at least 8 weeks, or you've been on a stable dose for at least 12 weeks.
- Your lung function (measured by FVC and DLCO) meets certain minimum levels.
- You haven't had a recent sudden worsening of your lung symptoms or a serious lung infection.
- You are willing to avoid smoking and excessive alcohol during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This study tests an experimental medicine called HSK44459 to see if it can slow down progressive pulmonary fibrosis (PPF), a condition that causes lung scarring and breathing difficulty. The goal is to learn if the medicine can help people keep more of their lung function compared to a placebo.
This trial tests the long-term safety and effectiveness of an oral medication (HSK44459) in people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. If you were in the earlier study profile, this study lets you keep taking the medication to see if it continues to help over time.
This study tests an experimental pill called SYH2059 for people with IPF, a condition that causes lung scarring and makes breathing harder. The goal is to see if the pill is safe and can help slow down the disease.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
Hear when a new IPF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.